Pediatric Oncology & Pathology Services

Pediatric Oncology & Pathology Services Anatomic Pathology Flow Cytometry Cytogenetics Pharma Services Diagnostic, Prognostic, Predictive, and Predisposition Testing

Pediatric Oncology & Pathology Services NeoGenomics Laboratories is fully focused on propelling cancer diagnostics and research forward. Innovation and quality are two of our core company values. We fulfill them in two main ways: We provide unique, efficient multi-method cancer reference testing services that respect the time and cost pressures of these critical patient care situations. We put the highest priority on anticipating, creating, and continually improving a business that is a true partner to cancer care practitioners and researchers in academia and industry. From test development to specimen transport, client services, billing, and throughout the organization, we pay close attention to what our patients and customers need and want. Pediatric oncology needs and deserves the best clinical diagnostic and research partners available. technology and immuno-oncology are providing new opportunities that, in combination with strong traditional diagnostics, are leading to significant progress. NeoGenomics is CAP-accredited, CLIA-certified laboratory providing the full spectrum of cancer reference services: consultation, flow cytometry, IHC, cytogenetics,, and molecular analysis. With 15 years' experience serving pathologists and oncologists in all types of cancer, NeoGenomics is renewing its focus on pediatric cancer to provide the best of these tools to the cancer community. 2 NeoGenomics Laboratories The molecular and biological characteristics of pediatric cancers are different from those in adult cancer. Our mission is to define these characteristics and to help physicians to better treat and manage these cancers. Maher Albitar, MD SVP, Chief Medical Officer & Director of R & D at NeoGenomics

NeoGenomics' Advantages Here are some of the reasons clients choose NeoGenomics. Comprehensive: We have expertise in all methodologies of cancer reference testing; molecular testing,, IHC/ISH, cytogenetics, and flow cytometry. We also cover all hematologic and solid tumor cancer diagnoses. Having all techniques available in one lab allows efficiency in ordering, shipping, tracking, and reporting; most effective use and test prioritization on small specimens; and potential for better case coordination with reduced turnaround times. Complete: Our services are not just broad, but also deep with more than 600 orderable tests. -- Most comprehensive molecular oncology menu in the US with over 155 tests for diagnostic, prognostic, predictive, and hereditary predisposition indications. -- 10-color flow cytometry with numerous full panels and follow-up 'short panel' options. -- Extensive libraries of heme panels, solid tumor probes, and IHC stains. Liquid biopsy: Options to bone marrow biopsy are especially important for pediatric patients. Our biopsy-free analyses target circulating hematologic or solid tumor DNA or RNA in easily-collected peripheral blood samples. We offer 14 hematologic disease liquid biopsies, and a 48-gene pan-cancer solid tumor profile. COG Certification in Cytogenetics: Confirming NeoGenomics high standards of quality in technical analysis and laboratory operations, we are certified to perform cytogenetics for the Children's Oncology Group. We are actively preparing for certification in flow cytometry. Rapidly-evolving test menu: With one of the most rapid test development cycles in the industry, NeoGenomics quickly develops diagnostics for newly-recognized biomarkers and adapts to new and changed clinical guidelines. In the years 2015-2017, we launched or enhanced over 150 tests. Ease of access: Our professional staff and support services are available at any time. Throughout our growth, we have worked to maintain 'small lab' approachability and to make quick connections between our clients and our internal medical and technical team members. Tech-only programs for pathologists: Client pathologists working with NeoGenomics may choose to review and sign out flow cytometry,, and/or IHC cases through our extensive technical-only or "TC/PC" program. Tech-only services are supported by live and recorded training, easy-to-follow User's Guides, custom reporting options, and a "push to global" option to refer especially complicated cases back to NeoGenomics pathologists for reporting. Pharma Services: Flexibility and rapid response all hallmarks of our Pharma Services. We support academic and industry researchers in all size and scope of projects. Commercial development efforts are simplified by access to our multiple CAP-accredited, CLIA-certified domestic labs as well as our European laboratory. NeoGenomics Laboratories 3

Pediatric Testing Highlights As we frequently add new tests and enhance existing ones, please see our website to view the most current menu and to sign up for new test notifications. Here are selected tests in the most common pediatric cancer indications. Leukemia, Lymphoma & Myeloid Disorders Selected Testing Indications: Acute lymphoblastic leukemia (ALL) Acute myeloid leukemia (AML) Acute promyelocytic leukemia (APL) Anaplastic large cell lymphoma (ALCL) Burkitt lymphoma Chronic myeloid leukemia (CML) Diffuse large B-cell lymphoma (DLBCL) Follicular lymphoma Hairy cell leukemia (HCL) Hodgkin lymphoma Juvenile myelomonocytic leukemia (JMML) Large granular lymphocytic (LGL) leukemia MALT lymphoma Mantle cell lymphoma (MCL) Marginal zone B-cell lymphoma (MZL) Mastocytosis Myelodysplastic syndrome (MDS) /Chronic myelomonocytic leukemia (CMML) Myeloproliferative neoplasm (MPN) Non-Hodgkin lymphoma (NHL) T-cell lymphoma NeoLAB Liquid Biopsies AML Profile BTK Inhibitor Acquired Resistance Panel MDS/CMML Profile Myeloid Disorders Profile FLT3 Mutation Analysis IDH1 Mutation Analysis IDH2 Mutation Analysis Inv(16), CBFB-MYH11 Translocation KIT (c-kit) Mutation Analysis KRAS Mutation Analysis NPM1 Mutation Analysis NRAS Mutation Analysis PML-RARA Translocation, t(15;17) RUNX1-RUNX1T1 (AML1-ETO) Translocation, t(8;21) BCR-ABL1 Standard p210, p190 NeoTYPE AML Prognostic Profile NeoTYPE Lymphoma Profile NeoTYPE MDS/CMML Profile NeoTYPE Myeloid Disorders Profile ALK (2p23) for Lymphoma ALL Pediatric Panel AML BCR-ABL1 MDS MPN NHL 4 NeoGenomics Laboratories

Brain Tumors Selected Testing Indications: Glioblastoma Gliomas ATRX Mutation Analysis EGFRvIII Analysis IDH1/2 Mutation Analysis MGMT Promoter Methylation Analysis NeoTYPE Brain Tumor Profile NeoTYPE Precision Profile for Solid Tumors BRAF Rearrangement EGFR Amplification MYCN (n-myc) Amplification PDGFRA Amplification Melanoma BRAF Mutation Analysis NeoTYPE Melanoma TERT Promoter Mutation Analysis BRAF Rearrangement NeoSITE Melanoma IHC PD-L1, 22C3 FDA (KEYTRUDA ) PD-L1 28-8 FDA All Cancers Tumor Mutation Burden (TMB) Universal Fusion/Expression Profile (1385 Genes) Sarcoma Selected Testing Indications: Osteosarcoma Ewing s Sarcoma Rhabdomyosarcoma Pediatric Sarcoma NGS Comprehensive Sarcoma Fusion Profile NGS Ewing Sarcoma Fusion Profile NGS Non-Ewing Sarcoma Fusion Profile NGS Pediatric Sarcoma Fusion Profile NGS Rhabdomyosarcoma Fusion Profile NeoTYPE Liposarcoma Fusion Profile DDIT3 (CHOP) EWSR1 MDM2 SS18 (SYT) Solid Tumors, All Types NeoLAB Solid Tumor Monitor Liquid Biopsy NeoTYPE Discovery Profile for Solid Tumors NeoTYPE Precision Profile for Solid Tumors Hereditary Cancer Inherited Bone Marrow Failure Panel Hereditary Cancer Susceptibility for Pediatrics See our website for all 600+ available tests. NeoGenomics Laboratories 5

Sample Reports Most clients take advantage of e-mail result notifications and download patient results through our secure online portal NeoLINK. Faxed and mailed reports are always available. Reports are designed to allow quick understanding of overall results, followed by detailed supporting information about the technical analysis, significance, clinical application of results, and references. Our multigene panels and multi-method NeoTYPE Cancer profiles include patient-specific summary results written by staff pathologists after consideration of patient clinical data provided, results, and possible interactions of multiple abnormalities when detected. NeoTYPE Cancer Profile Reports further include patient-specific diagnostic and prognostic interpretation, integration of and IHC data and images when performed, and comment on predicted utility or resistance to targeted therapies. Report features include: A. Test description D. Technical result detail including mutant C. Interpretation of pathogenicity, diagnostic E. List of genes tested allele frequency or fraction (MAF) B. Concise list of abnormalities F. References information, prognosis E Patient Name: Test, Test Patient DOB / Sex: 09/10/2007 / M Accession / Case No.: 9999999 / NTP15-999999 Genes Evaluated (by molecular analysis unless otherwise noted) ABL1 ASXL1 ATRX BCOR BCORL1 BRAF CALR CBL CBLB CBLC CDKN2A CEBPA CSF3R CUX1 DNMT3A ETV6 EZH2 FBXW7 FLT3 GATA1 GATA2 GNAS HRAS IDH1 IDH2 IKZF1 JAK2 V617F JAK2 Exon 12-14 JAK3 KDM6A KIT KRAS MLL MPL MYD88 NOTCH1 NPM1 NRAS PDGFRA PTEN PTPN11 RAD21 RUNX1 SETBP1 SF3B1 SMC1A SMC3 SRSF2 STAG2 TET2 TP53 U2AF1 WT1 ZRSR2 PL Nucleic acid is isolated from plasma, peripheral blood cells or bone marrow. The NeoTYPE Myeloid Disorders Profile A includes massive parallel sequencing and mutation analysis of the following 54 genes: ABL1: EX: 4-6 (AA: L184_R362); ASXL1: EX: 12 (AA: I574_R1541X); ATRX: EX: 8, 10-11 and 17-31 (AA: N199_C220, D1247_E1314, and K2283_V1568); BCOR: EX: All (AA: M1_W1755X); BCORL1: EX: All (AA: M1_1711X); BRAF: EX: 15 (AA: I582_M620); CALR: EX: 9 (AA: A352_L417); CBL: EX: 8 and 9 (AA: E366_K417); CBLB: EX: 9 and 10 (AA: E358_K469); CBLC: EX: 9 and 10 (AA: V429_V454); CDKN2A: EX: All (AA: M1_A167X); CEBPA: EX: All (AA: M1_A3580); CSF3R: EX: 14-17 (AA: A576_P830); CUX1: EX: (AA: M1_678X); DNMT3A: EX: All (AA: M1_V912X); ETV6: EX: All (AA: M1_C452X); EZH2: EX: All (AA: M1_P751X); FBXW7: EX: 9, 10 and 11 (AA: R473_G621); FLT3: EX: 13-15 and 20 (AA: S543_K647 and C807_N847); GATA1: EX: 2 (AA: M1_P73); GATA2: EX: 2-6 (AA: M1_G480X); GNAS: EX: 8 and 9 (AA: T105_Q176 and D196_D240); HRAS: EX: 2 and 3 (AA: M1_A83); IDH1: EX: 4 (EX: Y42_Q138); IDH2: EX: 4 (AA: F126_Q178); IKZF1: EX: All (AA: M1_S519X); JAK2: EX: 12 and 14 (AA: L509_F547 and S593_N622); JAK3: EX: 13 (AA: S596_L638); KDM6A: EX: All (AA: M1_S1401X); KIT: EX: 2, 8-11, 13 and 17 (AA: S24_R112, K412_F591, S593_N622, and C788_N828); KRAS: EX: 2and 3 (AA: M1_Y96); MLL (KMT2A): EX: 5-8 (AA: D1112_K1362); MPL: EX: 10 (AA: W491_Y521); MYD88: EX: 3-5 (AA: R192_P317X); NOTCH1: EX: 26-28 and 34 (AA: P1530_D1880, and E2061_K2555X); NPM1: EX: 12 (AA: A283_l294X); NRAS: EX: 2 and 3 (AA: M1_S87); PDGFRA: EX: 12, 14 and 18 (AA: K552_L595, L651_G668, and C814_S854); PHF6: EX: All (AA: M1_N365X); PTEN: EX: 5 and 7 (EX: A86_K164 and P213_K267); PTPN11: EX: 3 and 13 (EX: R47_R111 and V484_Q533); RAD21: EX: All (AA: M1_I631X); RUNX1: EX: All (AA: M1_481X); SETBP1: EX: 4 (AA: E858_Q919); SF3B1: EX: 13-16 (AA: E579_K741); SMC1A: EX: 2, 11, 16 and 17 (AA: K38_V99, V578_K637, and L808_N902); SMC3: EX: 10, 13, 19, 23, 25 and 28 (AA: L242_E268, R381_N435, D656_E705, E846_E881, K984_Q1035, and F1186_K1194); SRSF2: EX: 1 (AA: F57_R120); STAG2: EX: All (AA: M1_F1268X); TET2: EX: 3-11 (AA: M1_2002X); TP53: EX: 2-11 (AA: M1_Q331); U2AF1: EX: 2 and 6 (AA: K43_D72 and F117_M160); WT1: EX: 7 and 9 (AA: D367_T416 and V448_T477); and ZRSR2: EX: All (AA: M1_483X). When applicable, fragment length analysis is also performed on CALR and NPM1 to enhance the detection of low levels of insertion/deletion mutations. In addition, when applicable, confirmation of the presence or lack of mutation was performed using Sanger sequencing on the following genes: BRAF, HRAS, IDH1/2, KRAS, NRAS, PTEN and RUNX1.The sequencing method has a typical sensitivity of 5% for detecting mutations and the FLT3-ITD fragment analysis assay has a sensitivity of 5-10% for detecting FLT3-ITD in wildtype background. The CALR fragment analysis test has a sensitivity of 5% for detecting heterozygous insertion/deletions in the wild-type background. Various factors including quantity and quality of nucleic acid, sample preparation and sample age can affect assay performance. C M B SA A E Methodology Page 2 of 3 F D 6 NeoGenomics Laboratories

Working with NeoGenomics Clients appreciate working with NeoGenomics for our dedication to accuracy, service, and flexibility to resolve special challenges. Each department and program has dedicated staff and management, quality measures, and ongoing training. Billing: NeoGenomics offers client, thirdparty, and patient billing. Online payment options and patient payment programs are available. We are also contracted with a large number of private insurance plans and managed care organizations. Specimen Transport: We routinely use our own employee couriers with our company fleet of hybrid cars, highly-vetted contracted couriers, and commercial air/ground services to carefully coordinate pick-up, transportation, and receipt of patient specimens. Checkpoints and safeguards are monitored throughout the transport process. Client Services: Live telephone coverage is available 24/7 with extended coverage of all four US continental time zones. Client Service Advocates are cross-trained in multiple functions and support clients in all geographical regions. Online Ordering: NeoGenomics encourages clients to use our Online Ordering system as a green initiative, and because it improves our clients' efficiency and ours. Phone calls back to our clients' offices for missing information are reduced by 93% with use of Online Ordering. Get Started Now Call us at 866.776.5907 to speak with one of our physicians, lab directors, lab managers, Client Service Advocates, or Territory Business Managers. We'd love to learn how we might help enhance and simplify your testing process and help you in the care of your patients. NeoGenomics Laboratories 7

Recent Company Publications As an innovator, NeoGenomics is both an avid consumer and frequent contributor to the scientific literature. Please see below selected recent publications by NeoGenomics authors and collaborators. The full list is available on our website, along with downloadable files or links to contact us for copies. Publications 1. Gru AA, O Malley DP. Autoimmune and medication-induced lymphadenopathies. Semin Diagn Pathol. 2018;35(1):34-43. 2. Ma W, Brodie S, Agersborg S, et al. Significant improvement in detecting BRAF, KRAS, and EGFR mutations using next-generation sequencing as compared with FDA-cleared kits. Mol Diag Therapy. 2017;21(5):571-579. 3. Albitar AZ, Ma W, Albitar M. Wild-type blocking PCR combined with direct sequencing as a highly sensitive method for detection of low-frequency somatic mutations. J Vis Exp. 2017; Mar 29;(121). doi: 10.3791/55130. 4. Ahn IE, Underbayev C, Albitar A, et al. Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. Blood. 2017;129(11):1469-1479. 5. Albitar A, Ma W, DeDios I, et al. Using high-sensitivity sequencing for the detection of mutations in BTK and PLCy2 genes in cellular and cell-free DNA and correlation with progression in patients treated with BTK inhibitors. Oncotarget. 2017;8:17936-17944. 6. Naeini Y, Wu A, O'Malley D. Aggressive B-cell lymphomas: frequency, immunophenotype, and genetics in a reference laboratory population. Ann Diag Pathol. 2016;25:7-14. 7. Albitar F, Ma W, Diep K, et al. Deep sequencing of cell-free peripheral blood DNA as a reliable method for confirming the diagnosis of myelodysplastic syndrome. Genet Test Mol Biomarkers. 2016;20(7):341-345. 8. Aljurf M, Abalkhail H, Alseraihy A, et al. Chimerism analysis of cell-free DNA in patients treated with hematopoietic stem cell transplantation may predict early relapse in patients with hematologic malignancies. Biotech Res Intl. 2016; article ID 8589270. Poster Presentations 1. Wong C, Funari V, Ma W, et al. MDS diagnosis using cfrna profiling by targeted enrichment next generation sequencing. Poster #4268 presented at the 2017 Annual Meeting of the American Society of Hematology (ASH). 2. Ma W, De Dios I, Funari V, et al. Liquid biopsy as a diagnostic test for myelodysplastic syndrome and other acute and chronic myeloid neoplasms. Poster #4270 presented at the 2017 Annual Meeting of the American Society of Hematology (ASH). 3. O Malley D, Sudarsanam S, Chizhevsky V, et als. BRAF mutation and PD-L1 expression in melanoma: Comparison between multiple PD-L1 IHC clones and BRAF mutation evaluated by FDA-approved kits versus NGS. Abstract published in conjunction with the 2017 Annual Meeting of the American Society of Clinical Oncology (ASCO). J Clin Oncol 35, 2017 (suppl; abstr e21050) 4. Albitar M, Sudarsanam S, Ma W, et al. Correlation between MET gene amplification and TP53 mutation in upregulating PD-L1 expression in EGFR-wild-type lung cancer. Poster #5618 presented at the 2017 Annual Meeting of American Association for Cancer Research (AACR). 5. Au Q, Wong G, Padmanabhan R, et al. Integrated analysis of microrna, mrna, and protein expression utilizing MultiOmyx and NanoString from formalin-fixed paraffin-embedded lung, head and neck, breast, and melanoma tumors. Poster #1460 presented at the 2017 Annual Meeting of American Association for Cancer Research (AACR). 6. O'Malley D, Kim YS, Cheng L. Expression of platelet-associated marker CD42b on histoplasma. Presented at the 2017 Annual Meeting of the US and Canadian Academy of Pathology (USCAP). 7. Albitar A, Townsley D, Ma W, et al. Higher mutation rate in patients with aplastic anemia using peripheral blood cfdna as compared with bone marrow cells. Poster #3902 presented at the 2016 Annual Meeting of the American Society of Hematology (ASH). NeoGenomics Laboratories is a specialized oncology reference laboratory providing the latest technologies, testing partnership opportunities, and interactive education to the oncology and pathology communities. We offer the complete spectrum of diagnostic services in molecular testing,, cytogenetics, flow cytometry, and immunohistochemistry through our nation-wide network of CAP-accredited, CLIA-certified laboratories. Committed to research as the means to improve patient care, we provide Pharma Services for pharmaceutical companies, in vitro diagnostic manufacturers, and academic scientist-clinicians. We promote joint publications with our client physicians. NeoGenomics welcomes your inquiries for collaborations. Please contact us for more information. 12701 Commonwealth Dr., Suite 9 Fort Myers, FL 33913 Phone: 866.776.5907/ Fax: 239.690.4237 neogenomics.com 2018 NeoGenomics Laboratories, Inc. All Rights Reserved. All other trademarks are the property of their respective owners. MultiOmyx is a trademark of NeoGenomics, Inc, which holds a license from GE HealthCare BioSciences Corp. Rev. 041718